Reports preliminary quarterly revenue of approximately $1.3 million for the three months ended September 30, 2025 – the highest quarterly revenue since 2015 – with operational losses reduced to the ...

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...